Objective. Take-home naloxone (THN) is recommended in response to pharmaceutical opioid-related mortality. Some health professionals are reluctant to discuss THN for fear of causing offense. The aims of this study were to assess knowledge of opioid overdose and attitudes toward THN for opioid overdose reversal in people with chronic noncancer pain (CNCP).
Conclusions. Most participants had positive attitudes toward THN but low knowledge about opioid overdose symptoms. Strategies for educating patients and their caregivers on opioid toxicity are needed. THN may be best targeted toward those with risk factors in terms of overdose prevention and acceptability.
Introduction
There has been a substantial increase in opioid prescribing in many countries such as the United States, Canada, and Australia [1] . These increases have been accompanied by considerable increases in opioidrelated fatal and nonfatal overdose rates [2, 3] .
Naloxone, an opioid receptor antagonist, has an excellent safety profile and has long been administered in emergency medicine settings to reverse opioid-induced coma or respiratory depression [4, 5] . In some countries, naloxone can legally be distributed to laypersons for use in the event of an overdose. These programs have typically targeted interventions for people who use and/or inject illicit opioids [6, 7] . There is a growing body of evidence demonstrating reduced mortality, as well as enhanced knowledge of other overdose prevention and intervention strategies, following implementation of takehome naloxone programs [8, 9] .
People prescribed opioids for chronic noncancer pain (CNCP) have elevated risk of opioid-related mortality [10] [11] [12] , yet this group has traditionally not been the focus of take-home naloxone programs. People with CNCP commonly have risk factors for opioid overdose, such as use of a high opioid dose (e.g., >100 mg oral morphine equivalents); use of opioids with long halflives; concurrent use of other sedative medications (e.g., benzodiazepines, antidepressants) or alcohol; cooccurring mental health problems; and physical comorbidities such as respiratory illness and cardiovascular disease [10, [12] [13] [14] . Additional risk factors that have been described for some patients include challenging or unstable social circumstances, limited strategies to cope with pain, uncontrolled pain, and health service access barriers [10, 12, 13] .
Take-home naloxone programs have been developed in some US jurisdictions for people with CNCP. One study conducted in Wilkes County (North Carolina, USA) described take-home naloxone provision for pain patients who met criteria for overdose risk as part of a broader overdose prevention strategy [15] . Provision was justified on the basis of high frequency of overdose deaths in the home setting from pain medications, where family members could have intervened if they were aware of overdose signs and symptoms. Indeed, the updated (2016) Centers for Disease Control and Prevention (CDC) guidelines for prescribing opioids in chronic pain included a recommendation to provide naloxone where risk factors exist [16] .
One recent study, however, indicates that health professionals are reluctant to discuss take-home naloxone with patients for whom they prescribe opioid analgesics out of concern that the offer of naloxone may cause offense [10] . There is an additional concern that people with CNCP may hold the perception they are at lower risk of opioid overdose (due to prescription of the opioid by their doctor) and the provision of naloxone might result in stigma or being labeled a "drug user" [17] . No study has yet assessed whether these fears are warranted.
As such, the aims of the present study were to:
1. assess knowledge of opioid overdose symptoms among a sample of people with CNCP prescribed opioids;
2. examine attitudes toward naloxone supply for opioid reversal where opioids were prescribed for CNCP;
3. examine the association between attitudes toward naloxone supply and the presence of overdose risk factors and criteria established for naloxone supply programs.
Methods

Participants and Procedure
The Pain and Opioid IN Treatment (POINT) study was designed to document patterns of pharmaceutical opioid use, and risk of adverse events and outcomes, in a prospective cohort of people who were prescribed opioids for CNCP. The current study is based on a subset (N ¼ 208) of POINT study participants (N ¼ 1514) interviewed consecutively between September to October 2015 as part of the 24-month wave telephone interview (45 to 60 minutes' duration with $AUD60 reimbursement). Interviewers had received training in the computer interview content and had a minimum four-year health or psychology degree. The methodology of the larger cohort study has been described in detail elsewhere [18] . Procedures relating to data presented in these analyses are described below. The study was approved by the Human Research Ethics Committee of UNSW Australia (HREC reference: #HC12149).
At study enrollment, POINT participants were age 18 years or older; living with CNCP; taking schedule 8 opioids for CNCP for more than six weeks (schedule 8 opioids in Australia are strong opioids such as fentanyl, morphine, and oxycodone, where greater restrictions around storage and prescribing exist); competent in English; mentally and physically able to undertake telephone and self-completion interviews; and without serious cognitive impairments. A history of injecting drug use was not an exclusion criterion, but those currently prescribed pharmaceutical opioids for opioid substitution therapy (OST) for heroin dependence or taking opioids for cancer pain were not eligible.
Key Measures
The POINT study measures were based on recommendations made by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) expert group [19, 20] ; the full description of POINT study variables is described elsewhere. An additional module of 20 questions examining knowledge and perceptions around naloxone and opioid overdose was developed using items adapted from earlier studies with other clinical populations [7] (see Appendix A for wording and response options). The primary outcome measures used in this study are:
1) Opioid-Related Overdose Knowledge
Participants were asked to answer "true" or "false" to a series of statements about potential signs and symptoms of opioid overdose from section B of the Opioid Overdose Knowledge Scale (OOKS) [21] ; total scale scores ranged between 0 to 10, with higher scores indicating better knowledge of overdose signs and symptoms. In addition, they were asked about overdose symptoms using alternate wording developed with input from an expert panel (including pain clinicians, addiction clinicians and researchers), based on the suggestion that the word "overdose" may not be meaningful or salient to people with CNCP (see Appendix A).
2) Take-Home Naloxone Attitudes
Participants initially were given a description of naloxone and its role in reversing overdose, and after this description they were asked if they had ever heard of naloxone.
Further information about the concept of naloxone supply for people with CNCP was then provided for participants, who were then asked to rate this a "very bad idea," "bad idea," "neutral," "good," or "very good idea." Participants were also asked how they would feel if a health professional suggested they keep naloxone in their home in case of a severe overdose-like reaction to opioids.
3) Overdose Risk Factors and Eligibility Criteria for Naloxone Programs
We assessed a range of perceived risk factors that have been described to indicate appropriateness for naloxone supply. These risk factors were identified from a review of the literature with studies identified representing clinician perceptions, the broader overdose literature, and eligibility criteria for existing naloxone programs (see Appendix B for details) [10, [12] [13] [14] and included the following domains:
Medication-Related Risk. Four medication-related characteristics were identified and described below. Opioid dose in oral morphine equivalents (OME) [14, 22] was calculated from a self-completed medication diary that captured all medications taken in the week prior to the telephone interview. A binary variable identifying mean daily intake greater than 100 mg OME/d was computed based on evidence suggesting that individuals are at increased risk of overdose when this threshold is exceeded [12, 13, 23] . Methadone, antidepressant, and benzodiazepine use in the last week were also identified as perceived risk factors [10, [12] [13] [14] and extracted based on the past-week medication diary.
Opioid-Related Problems and Concerns. The Prescribed Opioids Difficulty Scale (PODS) was used to measure participants' current problems and concerns arising from their using their "opioid painkillers" [24] . The PODS measures self-report problems and concerns relating to opioids, including opioid-related side effects, tolerance, and addiction. Scores of 8 or higher were interpreted as indicating moderate-to high-level problems or concerns regarding their opioid medication.
Substance Use. Cannabis, tobacco, and nonmedical opioid use within the past 12 months were considered substance use risk factors (Appendix B). To evaluate alcohol use, we calculated summed scores on the brief Alcohol Use Disorders Identification Test (AUDIT-C). A score of 4 or higher was considered indicative of hazardous alcohol use for male participants-a score of 3 or higher for female participants [25] . Nonmedical benzodiazepine use, amphetamine use, and cocaine use were not reported due to the low frequency of use reported by participants in the past 12 months (<2% of the sample).
Physical and Mental Health Comorbidity. Self-reported physical comorbidities that affected respiration, kidney, or liver function were coded as a dichotomous variable [14] . Depression and generalized anxiety disorder were measured by the Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder (GAD-7) modules of the Patient Health Questionnaire [26, 27] . We used previously validated cutoffs for moderate to severe depression (defined as a score of !10 on the PHQ-9 [26] ) and moderate to severe anxiety (defined as a score of !10 on the GAD-7 [28] ).
Pain Severity and Pain Coping. The Pain Severity subscale score from the Brief Pain Inventory (BPI) was used to determine uncontrolled pain [29] . Pain severity scores of 7 or above indicate severe pain; severe pain despite long-term opioid treatment was used as a marker of uncontrolled pain [30] . The Pain Self-Efficacy Questionnaire (PSEQ) [31, 32] is a 10-item scale used to measure participants' confidence in a range of activities Chronic Pain, Opioids, and Naloxone and situations when they are in pain, rated on a seven-point scale (0 ¼ "not at all confident" to 6 ¼ "completely confident"). Scores lower than 30 suggest reduced ability to cope with pain and have been shown to be indicative of less sustainable treatment gains and predictive of lower rate of return to work and/or maintenance of treatment gains [33] .
Other Risk Factors. To represent unstable housing and social circumstances [10, 12] , participants who lived in owned or rented accommodation or with their family were coded as having stable housing, while the remainder were coded as unstable (e.g., living in boarding houses, institutions, squats, or caravans). We also identified participants with remote or outer regional postcodes, which may be associated with more difficulty accessing ancillary or emergency pain services [10, 13] .
Prior Opioid Overdose. Participants were asked if they had ever previously overdosed [12] [13] [14] . Due to concerns that the term "overdose" may not be salient for people with chronic pain, for this variable we coded positively participants who responded to any descriptions of overdose that were presented (described above).
Analyses SPSS Statistics version 22 (IBM, Somers, NY, USA) was used to calculate descriptive statistics: percentage for categorical outcomes and mean and standard deviation (M, SD) for continuous outcomes. We examined association between reported risk factors and attitudes to naloxone supply; odds ratios (ORs) and 95% confidence intervals (95% CIs) are reported for categorical variables, and t tests were used for continuous variables. Attitudes toward naloxone supply were recoded as a binary variable: positive attitude ("good" or "very good" idea) and neutral/negative positive attitude ("neutral," "bad," or "very bad" idea).
To examine if cumulative risk factors were related to a more positive attitude toward naloxone supply, we summed the number of risk factors and used Pearson correlation to examine association between risk scores and the five-point scale of naloxone supply of attitudes.
Results
Sample Characteristics
Just over half of the sample was female (N ¼ 122, 59%). The mean age of the sample was 60.1 years (SD ¼ 13.0). At baseline, participants reported having experienced CNCP for an average of 16.1 years (SD ¼ 12.4), and on average they had been prescribed opioids continuously for a mean of 7.0 years (SD ¼ 6.3).
Overdose History
Few participants reported ever experiencing an opioid overdose (5%, N ¼ 11) or overdose in the past year (2%, N ¼ 5). Eleven percent of participants (N ¼ 22) endorsed ever experiencing descriptions of "extreme" drowsiness and confusion from opioid medication. Eight participants (4%) reported that their medication "made them unconscious" and/or "difficult to wake up," and two participants (1%) reported that their medication "made their lips turn blue." In total, 30 participants (14%) endorsed at least one description of opioid overdose in their lifetime.
Knowledge of Overdose Signs and Symptoms
On average, participants were able to correctly answer fewer than half (mean score ¼ 4.5) of the 10 questions on opioid overdose symptoms correctly (Table 1) .
Knowledge and Attitudes Towards Naloxone for Opioid Reversal
Less than half the sample (41%) had heard of naloxone (Table 2) . Nonetheless, after having naloxone explained to them, over half (60%) reported that naloxone supply to patients prescribed opioids was a "good" or "very good" idea, with eight people (4%) reporting it was a "very bad idea." When participants were asked their thoughts on being personally offered naloxone, 60% reported that they either "would expect to be offered it" or "would appreciate being offered it." One in 10 endorsed that they "may feel a little offended if a health professional thought I may need this medication." Seven people endorsed the These data were collected from the first 62 participants. When it became apparent that participants found these questions difficult to comprehend/respond to (increasing the time burden in completing the interview), these items were dropped from subsequent interviews.
item "I would feel very offended if a health professional thought I may need this medication" (3%).
Risk Factors for Opioid Overdose
Two out of five participants (73 of the 195 who reported their total opioid consumption, 37%) reported that their mean daily opioid dose was greater than 100 mg OME, defined as a high-risk dose. One in three (N ¼ 70, 34%) reported benzodiazepine use, and one in four (54, 26%) met criteria for high-risk alcohol use (see Table 3 for full details of risk factors examined).
Attitude to Naloxone Provision and Risk Factors for Opioid Overdose
Men were more likely to report positive attitudes to naloxone supply than women (see Table 3 ). Positive attitudes toward naloxone were also associated with past year cannabis use and past year tobacco use. None of the other risk factors were significantly associated with attitude to naloxone supply.
On average, participants reported an average of five of the 18 possible perceived risk factors (mean ¼ 4.7, SD ¼ 2.6, range ¼ 0-12). We used Pearson correlation to examine the association between attitudes to naloxone (in the original five-point scale) and the sum of risk variables. The results did not indicate a significant association with the total risk count and attitudes toward naloxone (r ¼ 0.117, N ¼ 208, P ¼ 0.093).
Discussion
This is the first study to the authors' knowledge to characterize overdose knowledge and perceptions of take-home naloxone among people with CNCP. One in seven (14%) participants reported overdose symptoms, depending on the language used to describe opioid toxicity. Participants who completed the OOKS answered the majority of the questions incorrectly, suggesting that knowledge of overdose symptoms among this group is poor. Existing research shows that people who inject opioids are generally able to identify most symptoms without training, with further improvement following overdose training [7, 34] . This highlights the difference in baseline knowledge between these populations and has implications for translation of opioid overdose prevention interventions across contexts. Further, these findings highlight the importance of language when examining opioid "overdose." These findings should be considered in the context of how to explore adverse events related to opioid toxicity in chronic pain populations, as the choice of language and capturing outcomes (such as if medical attention was required) can alter the rates of overdose reported.
When the rationale behind naloxone supply for use at home was explained, the participants appeared open to the concept of naloxone provision. Typically, this sample thought that the supply of naloxone was a "good" or "very good" idea and they would expect or appreciate their doctor to discuss take-home naloxone with them; only a minority of participants reported that they would be offended if their doctor offered it to them. Participants reporting some overdose risk factors (e.g., past year tobacco and cannabis use) appeared more likely to be positive about naloxone provision, suggesting that targeting naloxone supply toward higher-risk patient groups would not only make clinical sense, but may be more acceptable to patients.
Given that opioids have a well-established risk of respiratory depression as a side effect, these findings suggest that there is scope for prescribers to educate patients and their significant others regarding overdose signs and symptoms. This is particularly relevant given that previous research has found that for most cases of prescription opioid-related mortality there is a family member or caregiver present [15] , indicating an opportunity for intervention. Importantly, findings suggest that education around opioid toxicity symptoms is needed if naloxone is to be supplied, so as to inform the decision as to the appropriate time to administer naloxone, and thus maximize potential efficacy of take-home programs in reducing mortality.
Furthermore, contrary to concerns cited by health providers [10] , only a minority of participants described negative attitudes toward being offered naloxone, and indeed, those at greater at risk were more supportive of being offered naloxone. This suggests that prescribers of opioid analgesics should at least discuss the risks of overdose and offer naloxone to patients at higher risk of opioid overdose. Further work is required to assist prescribers and other clinicians (e.g., pharmacists) to identify patients at greatest risk of opioid overdose. Training to assist health professionals in offering and delivering takehome naloxone interventions and the development of relevant consumer education resources that are appropriate to the needs of people with chronic pain are also required. An important factor in any such information is striking the right balance between empowering patients to reduce risks without causing inappropriate concern and contributing to existing fears around opioids.
Limitations
The nature of the study design means that the usual limitations of self-report data exist; however, the study design used many factors known to maximize the reliability of the self-report data (where participants were given assurances of confidentiality and there were no negative outcomes from honest reporting) [35] . The fact that participants were unable to answer questions on overdose knowledge correctly (or at all) suggests that familiarity with signs and symptoms of opioid overdose is poor among this group; questions were only asked of a subset (N ¼ 62) due to participants having such difficulty with the questions, limiting the potential analyses with this data. A further limitation is that no current measure of opioid overdose risk has been prospectively validated in pain patients. While not empirically validated, this study included an examination of potential overdose risk factors, including those developed with clinician and expert input. As such, these indicators represent how clinical staff may currently identify people suitable for take-home naloxone. It should be noted that not all risk factors are equal and the extent to which the current study's measures predict patient outcomes is unknown. Further work is critical to establish empirically derived risk factors, which may in-turn better target prevention strategies in patients prescribed opioids.
Conclusions
In summary, most participants had positive attitudes toward being offered naloxone, but their knowledge of overdose signs and symptoms was generally low. In the face of rising pharmaceutical opioid-related mortality in many Western countries, there is an urgent need to develop and evaluate strategies for educating patients and their caregivers on the signs and symptoms of opioid toxicity. Naloxone information may be best targeted toward those with risk factors, both in terms of overdose prevention and acceptability.
